News

IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam

GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company…

3 days ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the…

3 days ago

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

3 days ago

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic…

3 days ago

VA STAND Act introduced in the United States Senate

Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord…

3 days ago

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

New studies at Mount Sinai Health System and Penn Medicine investigate how the brain controls movementNEW YORK, March 22, 2024…

3 days ago

Angle PLC Announces Parsortix at European Breast Cancer Conference

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two posters highlighting the utility of…

4 days ago

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S.…

4 days ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a…

4 days ago

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the…

4 days ago